Data as of Apr 15
| -0.11 / -2.50%|
Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company, which is focused on the sales, marketing and development of branded and generic pharmaceutical products for the pediatric market. Its pediatric products are focused on allergy and upper respiratory, including nasal, chest congestion and cough, antibiotics, and dermatology. Pernix Therapeutics Holdings branded products CEDAX, an antibiotic for middle ear infections; NATROBA, which is a topical treatment for head lice; OMECLAMOX-PAK, a ten-day therapy of omeprazole delayed-release capsules, clarithromycin tablets and amoxicillin capsules for the treatment of helicobacter pylori infection and duodenal ulcer disease; and REZYST, which is a probiotic blend to promote dietary management. The company promotes its branded pediatric and generic products through its sales force wholly-owned subsidiary, Macoven Pharmaceuticals. Pernix Therapeutics Holdings was founded in November 1996 and is headquartered in The Woodlands, TX.
|Douglas L. Drysdale||Chairman, President & Chief Executive Officer|
|Terence S. Novak||Chief Operating Officer|
|Tracy Simmons Clifford||CFO, Secretary, Treasurer, CAO & Finance Director|
|Brian T. Dorsey||Senior Vice President-Research & Development|
|Cooper C. Collins||Chief Strategy Officer|